Join us for an exclusive event on Advanced Biomaterials for 3D Printed Medtech and Biotech, where leading experts, innovators, and researchers will explore cutting-edge materials shaping the future of healthcare. From bioresorbable polymers and nanocomposites to cell-compatible hydrogels and innovative scaffolds, this event highlights how advanced biomaterials are driving breakthroughs in medical devices, bioprinting, regenerative medicine, and drug delivery. Perfect for entrepreneurs, clinicians, scientists, and investors, attendees will gain insight into the latest R&D trends, regulatory pathways, and commercialization strategies transforming the medtech and biotech industries through 3D printing.

Speakers:

Janaina Dernowsek

Janaina de Andréa Dernowsek, PhD, is a scientist, entrepreneur, and global leader in the fields of 3D bioprinting, biofabrication, and regenerative medicine. With a doctorate in Genetics, three postdoctoral fellowships in biofabrication, and an MBA in Innovation, Business, and Leadership, she combines deep scientific expertise with strategic vision. As co-founder and CEO of Quantis Biotechnology and BioEdTech, Janaina has been at the forefront of developing human extracellular matrix–based biomaterials and next-generation biofabrication technologies. Her work bridges fundamental biology with advanced engineering, enabling applications in healthcare, aesthetics, and education.

Driven by a mission to transform innovation into impact, Janaina has spent over a decade advancing biofabrication through research, entrepreneurship, and education. She has led pioneering projects on human-derived extracellular matrices, 3D bioprinted tissues, and customized bioprinters, while also training professionals worldwide in hands-on biofabrication methodologies. Recognized for her role in shaping the future of deep tech in health, she actively contributes to international collaborations, scientific dissemination, and the creation of scalable biotech solutions that redefine the boundaries of human health and longevity.

Riccardo Levato

Associate Professor of Translational Bioengineering and Biomaterials at the Department of Clinical Sciences (Faculty of Veterinary Medicine, Utrecht University), and at the Department of Orthopaedics of the University Medical Center Utrecht. Principal Investigator at the Regenerative Medicine Center Utrecht. Prior to moving to Utrecht, he worked in several research groups across Europe: 3Bs, University of Minho (Portugal); BioMatLab, Technical University of Milan (Italy), Institute for Bioengineering of Catalonia (IBEC, Spain), and he holds a cum laude PhD in Biomedical Engineering from IBEC and from the Technical University of Catalonia. Since 2020 he was awarded a Starting grant from the European Research Council on the development of a novel volumetric bioprinting technology for organoid research and to engineer functional bone marrow analogues in vitro. Since 2021, he is coordinator of a European consortium (ENLIGHT, Future and Emerging Technologies scheme, European Innovation Council pilot), aiming at developing biofabricated pancreas to study treatments for diabetes.

He published more than 85 peer-reviewed articles international journals, and he was conferred several awards including the 2016 Wake Forest Institute for Regenerative Medicine Young Investigator Award, the 2021 Jean Leray award from the European Society for Biomaterials, the 2022 Robert Brown award from the Tissue Engineering and Regenerative Medicine International Society, and the 2023 Mid-career Investigator Award from the International Society for Biofabrication (ISBF). Riccardo is also serving on the Board of Directors of ISBF.

Jasper Van Hoorick

Dr. Jasper Van Hoorick, PhD, is the co-founder and Chief Executive Officer of BIO INX, a spin-off from Ghent University and Vrije Universiteit Brussel that specializes in advanced biomaterials and bio-inks for high-resolution 3D bioprinting and biofabrication. With a background in polymer chemistry, he earned recognition for his innovative work early on—receiving the Agoria award in 2014 for his master’s thesis in tissue engineering. His doctoral research, supported by an FWO grant, focused on developing biodegradable polymer materials for ocular tissue regeneration, especially through multiphoton lithography techniques, culminating in a summa cum laude PhD in 2019 and the prestigious Solvay award in 2020 .

Since founding BIO INX in 2022, Jasper has driven the company’s mission to transform the field of regenerative medicine by bridging rigorous academic research with practical, real-world applications. Under his leadership, BIO INX has become a global player in 3D bioprinting, developing bio-inks that not only enable tissue printing at micrometer and nanometer resolution—but which also hold promise for replacing animal testing and, ultimately, printing functional organs.
The company is already pioneering materials for Light-based cell-printing technologies so precise they can reproduce intricate tissue architectures, and is even collaborating on the development of artificial miniature hearts aimed at space-based aging studies. Which explains BIO INX’ slogan: ‘From Light to Life”.

Bowman Bagley

Bowman Bagley is Vice President of Commercial at CollPlant, where he is leading the introduction of recombinant human type I collagen and its methacrylated derivative to the U.S. market for applications in cell culture, tissue engineering, 3D bioprinting, and medical devices. He brings nearly a decade of leadership experience from Advanced BioMatrix, a global supplier of purified collagen and extracellular matrix products, where he served as Chief Executive Officer.

At Advanced BioMatrix, Bowman helped develop and commercialize more than 100 products—including bioinks for extrusion, DLP, 2PP, and volumetric bioprinting—while driving growth across product development, business development, and global sales. He holds a B.S. in Neuroscience from Brigham Young University and an MBA from the University of Utah.

Scott Taylor, PhD

Dr. Scott Taylor is the Chief Technology Officer at Poly-Med and specializes in material selection and medical device design. He has worked on development teams for more than twenty marketed medical devices and is experienced in the creation of novel materials and processes, product design and development, advanced manufacturing services, application and development of intellectual property, as well as physical and chemical testing protocols.

Dr. Taylor has undergraduate degrees in physics and mechanical engineering from Furman University and Clemson University, respectively, and completed his doctorate in Bioengineering from Clemson University. Through his tenure, Dr. Taylor has published numerous papers and conference abstracts, several book chapters, and is inventor for more than twenty-five (25) US and international patents. In addition to his position at Poly-Med, he maintains an appointment as adjunct faculty of Bioengineering at Clemson University.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

The post Advanced Biomaterials for 3D Printed Medtech and Biotech appeared first on 3DHeals.

Integrating 3D printing technologies into microfluidic device fabrication has significantly advanced the field. Rapid prototyping and complex geometries are not easily achieved with traditional methods like soft lithography. Stereolithography (SLA) and two-photon polymerization can create exact, intricate microfluidic structures. Despite these advancements, challenges remain, particularly concerning material properties. Many 3D-printed materials lack the optical transparency and biocompatibility essential for biological applications. Requirements for higher-resolution for next-generation microfluidics continues to be a hurdle. To explore these developments further, 3DHEALS welcomes you to join our virtual event focusing on “Microfluidic Devices and 3D Printing” on April 17, 2025. This event gathers industry experts, scientists, designers, and entrepreneurs to provide insights into the latest trends and developments in the field. For more details and registration information, please visit the 3DHEALS events page.

Speakers:

Hemdeep Patel

Hemdeep brings over 30 years of business and entrepreneurial experience to his role as co-founder of CADWorks3D. An early adopter of 3D printing (2009), he recognized the waves 3D printing would make for manufacturing processes across various industries – and he knew he needed to be part of this movement. With a background in Physics and Astronomy, when he discovered the applications of 3D printing in scientific fields, particularly in microfluidics, the path was paved.

Paul Marshall

A mechanical engineer with 25 years professional experience, Paul has been involved in the Life Science sector for the last 10. He founded Rapid Fluidics in 2020 to provide a genuine rapid-protoype service to the microfluidics sector, based on the development of the process to meet the unmet need that he had experienced.

Christopher Moraes

Chris Moraes is a hybrid engineer: he trained in nanoengineering (B.A.Sc.), and switched into mechanical and biomedical engineering (Ph.D, U. Toronto) before holding a Banting / NSERC postdoctoral fellowship at the University of Michigan’s Biointerfaces Institute. His research interests lie at the interface between engineering, biology and medicine, and he is particularly curious about the role microenvironmental biomechanical forces play in driving disease and development.

Jeff Schultz, Ph.D., MBA

Jeff Schultz, co-founder of Phase, has more than 20 years’ experience developing novel 3D printing techniques for a wide range of applications. Now, with the support of 3 NIH grants, Schultz is focusing on developing a novel way to 3D print microfluidics to make organ-on-a-chip models more commercially applicable and accessible.
He earned his Ph.D., M.S., and B.S. in materials engineering from Virginia Tech, where his research focused on understanding the ranges of physical, rheologic and thermodynamic properties that made a polymer suitable for selective laser sintering additive manufacturing. Schultz then became a principal partner in a start-up 3D-printing company which developed metal additive manufacturing technology and aerodynamics instrumentation. There, he led technology development and was the first inventor on all the key patents related to its additive friction stir technology. After exiting the company, Schultz earned his MBA from MIT and then built the US additive manufacturing business unit for Oerlikon Corporation, a Swiss industrial conglomerate. The facility he grew and led at Oerlikon was among the largest additive manufacturing component production facilities globally.

After a successful scale-up at Oerlikon, Schultz returned to entrepreneurship and co-founded Phase, his second startup focused on developing additive manufacturing technology. The company has received support from the NIH, NC Biotech, and the State of North Carolina, and has 5 patents in various stages related to its novel 3D printing and VivorrayTM technology.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

The post Microfluidic Devices and 3D Printing appeared first on 3DHeals.

3DHEALS is kicking off its first in-person/hybrid event in 2025 in San Francisco, welcoming investors, entrepreneurs, and innovators in the space. The healthcare industry is transforming, driven by 3D printing and bioprinting technologies redefining patient care. This exclusive in-person event offers an opportunity to explore the latest advancements in custom prosthetics, implants, bioprinted tissues, and scaffolds. Engage with top medical professionals, engineers, and industry pioneers in charge of this rapidly growing sector. For investors, this event is a gateway to high-growth opportunities in healthcare and advanced manufacturing. With global demand for personalized medical solutions rising, 3D printing is set to disrupt traditional supply chains and unlock new revenue streams. Connect with startup founders, industry executives, and R&D leaders driving the commercialization of these technologies. Whether you’re looking to fund the next breakthrough or gain strategic insights into this expanding market, this is an event you won’t want to miss. Secure your place today.

Speakers:

 

Josh Mikulich

Implants & medical technologies sales leader with an emphasis in spinal endoscopy, previously focused on open spine procedures, joint reconstruction, thoracic oncology, and biologics. Currently employed with Arthrex in the spinal endoscopy division. Spinal endoscopy is the most minimally invasive surgical procedure for neural decompression surgery.

Formerly employed with Anatomics as Senior Product Specialist with work involving groundbreaking patient-specific implants mostly for oncology use.

 

Bhushan Mahadik

Dr. Mahadik received his PhD in Chemical and Biomolecule Engineering at the University of Illinois at Urbana Champaign. His expertise is in the field of tissue engineering, stem cell biology and 3D printing. He was the Assistant Director at the NIH Center for Engineering Complex Tissues (CECT) at the University of Maryland that focused on novel applications of 3D printing and bioreactor technologies. Presently, he is the Director of Research at Prellis Biologics with a focus on using 3D Lymph Node Organoids for the development of new clinically relevant antibodies.

He shares a deep interest in Regenerative Medicine and its applications in the clinical space, ranging from implantable scaffolds for repair and regeneration, to the development and assessment of new therapies using complex in vitro models that recreate native biology.

 

Rajan Patel

Rajan Patel has over three decades of expertise in driving innovation and advancing commercialization in the healthcare industry. His extensive background encompasses diagnostics, critical care, patient monitoring, and drug delivery technologies. At iO Life Science and iO Life Ventures, he leads the incubation of transformative technologies, overseeing a diverse portfolio of over 20 startups. With significant investment experience and a strong commitment to fostering progress in healthcare, Rajan has played a pivotal role in accelerating the development and commercialization of innovative medical devices. His leadership contributions span renowned companies such as MiniMed, Heartport, Aerogen, M2 Medical, and Cirtec Medical.

As the CEO of Kallisio, Rajan is at the forefront of advancing patient-specific medical devices, addressing key side effects of cancer therapy, such as oral mucositis and other oncology-related complications. Kallisio is dedicated to driving personalized medicine through innovative solutions that enhance treatment precision and improve patient outcomes. These technologies reflect Kallisio’s broader mission to mitigate the adverse effects of cancer therapy, equipping clinicians with tools to deliver precise, effective, and patient-centered care.

 

Kuan-Lin Chen

Dr. Kuan Lin Chen is an orthopaedic surgeon specializing in hip and knee replacement, as well as complex joint reconstruction following musculoskeletal tumor resection. He also serves as a medical advisor at AMED Ventures. With a background in bioengineering from UC Berkeley, he has a strong foundation in medical device design and innovation. In addition to his clinical and advisory roles, he actively lectures at universities on strategic design thinking in medical technology.

A prolific innovator, Dr. Chen holds several patents and made history as the first resident doctor to license technology from his home academic institution to a company. His passion for bridging clinical needs with cutting-edge solutions led him to his advisory role at a Medtech venture group in the Bay Area, where he provides evidence-based analysis to drive investment and development strategies.

 

Jesse Courtier

Jesse Courtier, is a Healthcare Investor, Entrepreneur, and Pediatric Radiologist. He is current Managing Partner of Healthcare GT Ventures, a new Venture Studio/Venture Platform. He founded Sira Medical, a venture backed UCSF spinout using Augmented Reality for pre-surgical planning and worked to bring this from idea to FDA 510k cleared application. His interests lie in the application of innovative technologies that positively impact patient lives and improve physician workflow efficiency and well-being.

 

Moderator:

 

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

The post San Francisco: 3D Printing and Bioprinting for Health appeared first on 3DHeals.

There were too many pessimistic headlines in 3D printing in 2024!

Discussing anemic machine sales is a waste of time.

In 1960, Theodore Levitt warned that America’s railroad industry declined because railroads assumed they were in the “railroad business rather than in the transportation business.”  Companies miss out on long-term growth when they fail to see the full spectrum of customer needs.

But that’s not everyone.

Many public and private companies have changed their focus and directions, understanding that healthcare, advanced manufacturing, robotics, specialty materials, and biotechnology are better at guiding a company’s mission statement than selling more machines, which is also essential.

Since 2018, 3DHEALS has been a platform connecting founders, investors, key operators in healthcare 3D technologies through the Pitch3D program. Since then, we have connected more than 70 companies to 30 institutional investors and angel investor groups. This upcoming event would be the first official event around Pitch3D, where we will virtually invite some of our investors, startups, and advisors to join us and kickoff a new year before the JP Morgan annual conference in San Francisco.

You can subscribe here to receive future emails.

Speakers:

Investor Panel:

Nicole Black

Nicole Black, PhD is the Program Director for MedTech Innovator, a nonprofit supporting early-stage and mid-stage medical device and diagnostics startups. Nicole grew up in Michigan before attending Boston University to study Biomedical Engineering as a Trustee Scholar. In 2020, Nicole completed her PhD at Harvard University, working on interdisciplinary medtech projects between the Wyss Institute for Biologically Inspired Engineering and Mass Eye and Ear hospital. After graduating, Nicole launched a startup company, Beacon Bio, based on her PhD work as a Gliklich Healthcare Innovation Scholar developing regenerative materials for 3D printing tissue grafts. Following Beacon Bio’s acquisition by Desktop Metal, Nicole served as the Vice President of Biomaterials and Innovation in their Desktop Health division. Nicole’s accolades include the Collegiate Inventors Competition Graduate Winner (2018), the Baxter Young Investigator Award (2020), the Lemelson-MIT Student Prize (2021), and the MIT Technology Review Innovators Under 35 (2023).

Peter Mercelis

Peter Mercelis is a medical device and 3D printing entrepreneur who has been active in 3D printing
industry since 2003. After his PhD on 3D printing of titanium, he became cofounder and CEO of
LayerWise, a pioneer in titanium 3D printing. LayerWise quickly became a market leader in medical
device and high-tech metal 3D printing. After being acquired by 3D Systems, Peter worked a few more
years at 3D systems, shaping the medical division of 3D Systems.

Since 2018, Peter returned to his entrepreneurial roots and became active as investor/advisor in several
3D printing and healthcare startups (Aerosint, Antleron, Amnovis, Oqton, Additive Lab and Onicor). In
2022 Peter co-founded Replasia, a startup focused on developing innovative hardware and software
solutions in the hip preservation domain. He will also participate in the Pitch3D section of this event in addition to the investor panel.

Jesse Courtier, MD

Dr. Jesse Courtier is Chief of Pediatric Radiology at UCSF Benioff Children’s -San Francisco, Founder of Sira Medical, a venture backed UCSF spinout in the Augmented Reality space, and serves as an advisor to a number of accelerators and VC firms including KidsX and Avon River Ventures. He has over a decade of clinical practice and clinical operations experience in the healthcare space, with special expertise in Pediatric Radiology and MRI. He was key in the initial prototype development, fundraising, team building, clinical pilot efforts, and FDA 510(k) clearance at Sira Medical. He is experienced in clinical research and has been the recipient of institutional, societal, and industry grants.

Operator Panel:

Mr. Julian Chan

Mr. Julian Chan graduated Magna Cum Laude from Brown University with a degree in business economics, as well as political science. He subsequently graduated from The University of Pennsylvania Law School.

He began his career at a software services start-up, Peritus Software Services, Inc. As acting General Counsel, he helped grow it from 30 employees to a company with over 500 employees and offices in five locations and four countries and $40 million in yearly revenue. He negotiated over $100 million in complex software licenses, service agreements, service licenses and software development agreements. He managed multiple rounds of venture capital totaling in excess of $20 million. He was involved in the acquisition of several companies for a total compensation in excess of $90 million, managing the integration of their legal teams and processes under him. Mr. Chan led legal efforts resulting in a 1997 IPO on Nasdaq, which raised $60 million.

Mr. Chan later founded the Wellspring Angel Fund and the Idealflow Angel Fund along with several founders of Intel, Global Crossing, JDS Uniphase, Gemstar, and other similar companies. He ran its incubator, managed review of all potential investments, negotiated investments in twelve start-ups, and led a team of four personnel in order to develop ideas originated by partners of the fund.

Later Mr. Chan served as the C.O.O. and General Counsel for Univessence Digital Studios, Ltd, at the time one of the largest distributor of games in China, distributing exclusively games such as “World of Warcraft” and “MU”. While he was there, Univessence, a Bermuda company, grew to having over 25 subsidiaries in China, Hong Kong, Japan and the US, approximately 300 employees, and $300 million in revenue. A sample of the work handled by him includes; incorporating the parent company and several key subsidiaries; completing the complex merger of the Bermuda parent company with Junnet, Inc, a BVI company, and conducted due diligence on its 20 Chinese subsidiaries; negotiating $30 million in international venture capital financing transactions; and drafting of key agreements with major game companies such as Sega, for exclusive territorial rights to China.

For a period of four years, he oversaw production at Media Revolution LLC, at the time one of the largest interactive marketing agencies in Los Angeles with clients such as Sony, Walt Disney, Warner Bros, Nestle, Honda, Coca-cola and Kyocera. He negotiated all internet marketing agreements, entertainment marketing and distribution agreements, traditional entertainment production agreements, and wireless content creation/distribution agreements during his time there. In his private practice, he has represented a billion dollar internet retailer, many internet businesses, consumer product developers, internet marketing companies representing fortune 500 clients, several best-selling authors, film production companies, and the official North and South American representative for the Shaolin Temple.

In recent years, his client base has expanded to more than 400 clients, including Newegg, Bytedance, Gushcloud and Huberman Labs.

Mr. Chan has served as the General Counsel of the National Association of Asian American Professionals, Chairman of the Southern California Monte Jade Science and Technology Association, assistant secretary and senior advisor to the Shaolin Foundation, and as Chairman of FF Fraternity – Los Angeles Lodge. He also worked to review distressed charities on behalf of the United Way.

He is licensed to practice in Massachusetts and California.

Tom Anderton

Tom Anderton is currently a partner at K&L Gates, where his practice focuses on transactional and IP work exclusively in the Life Sciences.  He currently represents cutting edge 3D bioprinting companies.  He was formerly General Counsel, Secretary at Mindray/Zonare Medical Systems and Vice President, Intellectual Property & Legal Affairs at Presido Pharmaceuticals where he oversaw the legal function at Presidio.  Before Presidio, he was the Associate General Counsel and Chief Patent Counsel at Monogram Biosciences, Inc., where he built Monogram’s IP portfolio which then was consistently recognized as one of the best IP portfolios in the US.  Before going to Monogram, Tom was the Lead Attorney, Oncology at Genencor, Inc. where he developed and implemented Genencor’s oncology IP portfolio and led the due diligence team in their in-licensing of BL22, a lymphoma compound developed in Ira Pastan’s lab at the NCI.  Prior to that, Tom was responsible for envisioning, creating, developing and implementing the patent strategy and portfolio related to the ‘virtual’ kinase, phosphatase and protease genes that SUGEN cloned from J. Craig Ventner’s early human genome sequencing efforts and involved in developing the portfolio that relates to the current Pfizer compound SU11248 (SUTENT).  In private practice as a young associate, Tom drafted and prosecuted some of the early VEGF-related patents.  Before working in the biotech arena, Tom was focused on appellate, constitutional and First Amendment law and was responsible for co-writing trial briefs in the ISKCON v. City of Los Angeles (Hare Krishna/LAX) First Amendment case(s).  Tom earned a J.D. from the Vermont Law School, a B.S. in molecular biology from UCSD, and an M.S. in Cancer Biology from Stanford University.  He has been consistently recognized by his peers as one of the most influential IP practitioners in the United States.  He is a member of the State Bar of California and is registered to practice before the United States Patent and Trademark Office.

Adele Wang

Adele has over 18 years of experience in corporate finance, banking and M&A. Over the last 7 years she has worked with a number of biotech and professional services companies to build efficient operations and financial reporting to catalyze growth and shepherd them through sell-side preparation and M&A exists. She is meticulously focused on strategy as well as execution.

Steven Donaldson

Steven Donaldson is a founder and principal at RadiantBrands, a full-service branding and marketing agency that provides brand strategy, naming, design, digital communications strategy, and campaigns to a wide range of clients, from start-ups to Fortune 100 companies.

Donaldson and his agency focus on brand storytelling. Who are you as a brand? Why would customers want you? With over twenty-five years of experience in branding and marketing, and currently consults with startups and is a regular advisor at the UC Berkeley-sponsored SkyDeck incubator.

Pitching Startups:

Eric Bennett

Eric is a serial entrepreneur with expertise developing advanced technologies. Prior to Frontier Bio, he was the CTO at Aether, producing low-cost, feature-rich bioprinters. His extensive scientific background covers brain-computer interfacing, optogenetics, microfluidics, DNA assembly, in addition to bioprinting. He earned a Master’s degree in Biomedical Engineering, with his research centering on the use of optogenetics and brain-computer interfacing to study and mitigate neural disorders. Eric is committed to creating transformative technologies that push the frontier of what’s possible.

Gurkaran Chowdhry

Co-Founder and Director of Business Development at 3DBioFibR. My background is in polymer physics and rheology, which I applied in developing a novel biopolymer fiber fabrication technology. This patent-issued dry-spinning technology has over 3600 times the throughput of competing technologies. at 3DBioFibR, we are using this technology to solve biomaterial challenges in medical, defence, and industrial applications.

David Pearlstone

Dr. Pearlstone is a founder/principal and CEO of DICOM Director. LLC. Previously, he was Executive Director of HealthHavenHub, a digital healthcare incubator in New Haven, CT,. Prior to that, Dr. Pearlstone had a long career in academic medicine, previously serving as Medical Director for Vitas Healthcare of Connecticut, Director of Breast Services at Hackensack University Medical Center, and Associate Chairman of Surgery, Chief of Surgical Oncology, and Director of Surgical Research at Lincoln Hospital in New York City and as Assistant Professor of Surgery at Yale School of Medicine, Dr. Pearlstone graduated from Phillips Exeter Academy and received his B.Sc. with Honors from Vanderbilt University in Nashville, Tennessee. Following a research fellowship at the Howard Hughes Medical Institute at Vanderbilt, he received his MD from New York University in 1989. He completed his residency in general surgery at NYU, including two years as a Clinical Research Fellow at Memorial Sloan-Kettering. He then went on to complete a clinical fellowship in surgical oncology at the M. D. Anderson Cancer Center in Houston, Texas. Dr. Pearlstone has worked in biomedical technology transfer since 2002, serving on the faculty of Clemson University College of Engineering in Clemson, SC, and the Stevens Institute of Technology in Hoboken, NJ. In 2010, Dr. Pearlstone received his MBA from the Leadership in Healthcare program at the Yale University School of Management.

Brad Estes

Dr. Estes received his Ph.D. from Duke University in Biomedical Engineering with an emphasis in chondrogenesis of fat-derived stem cells. Before earning his Ph.D., Brad served as the Manager of Research and Development in the spinal orthopedic division of Medtronic where he oversaw commercialization of medical devices from conception to market, including the achievement of regulatory approval for class III medical devices. He was also integrally involved in seeking intellectual property protection for the innovative products Medtronic was producing. In addition, Dr. Estes has acted as a consultant for both small and large medical device companies. In total, he has over 25 years of industry experience and holds 55 patents associated with medical devices. In his current role, Brad oversees all aspects of CytexOrtho operations with a focus on growth and success. In this position, he provides strategic leadership and sets the vision and direction for the company. His responsibilities include guiding research and development efforts, forging strategic partnerships, securing funding, and ensuring regulatory compliance. Additionally, he plays a hands-on role in fostering a collaborative and dynamic work culture, driving motivation and creativity among the tight-knit team at CytexOrtho.

Stephanie Willerth

Dr. Willerth is the C.E.O. and co-founder of Axolotl Biosciences – an award winning start-up focused on producing novel bioinks for 3D printing human tissues.

Renee Ryan

PinPrint

Renee Ryan is recognized as an industry insider and leading investor, deal-maker, and passionate innovator. She has over 25 years of building category-creating healthcare companies. Recently, Renee served as CEO and Board member of Cala Health, a pioneer in the field of wearable neuromodulaton therapy having launched two generations of product and consistently doubled revenue each year of her leadership. Previously, she led the medical technology investments for Johnson & Johnson Innovation (JJDC) on the West Coast and Asia Pacific for 8 years. While at J&J, she made over 15 new investments, including the Series A for Cala Health. Other investments include Auris Health, Verb Surgical, PowerVision and Tusker Medical, all of which led to significant acquisitions. Previously, she was a healthcare investment banker at Goldman Sachs and Jefferies. She currently sits on the Boards of RefleXion Medical and Neuropace (NPCE).

Peter Mercelis

Peter Mercelis is a medical device and 3D printing entrepreneur who has been active in 3D printing
industry since 2003. After his PhD on 3D printing of titanium, he became cofounder and CEO of
LayerWise, a pioneer in titanium 3D printing. LayerWise quickly became a market leader in medical
device and high-tech metal 3D printing. After being acquired by 3D Systems, Peter worked a few more
years at 3D systems, shaping the medical division of 3D Systems.

Since 2018, Peter returned to his entrepreneurial roots and became active as investor/advisor in several
3D printing and healthcare startups (Aerosint, Antleron, Amnovis, Oqton, Additive Lab and Onicor). In
2022 Peter co-founded Replasia, a startup focused on developing innovative hardware and software
solutions in the hip preservation domain. He will also participate in the Pitch3D section of this event in addition to the investor panel.

Abel Teo

Abel is a co-founder and the CEO of Castomize Technologies. Providing leadership and direction to the company, he steers the overall strategy of Castomize to grow and deliver long-term value to healthcare ecosystems in Singapore and beyond. Since the inception of Castomize, Abel has established multiple collaborations with clinicians, universities, and distributors in Asia. He also led fundraising efforts for the Castomize, successfully raising half a million Singapore dollars. Under his leadership, the team attained the ASEAN outstanding engineering achievement award, and the founding team was included in the Forbes Asia 30 Under 30 list for healthcare and science.

Alyssa Huffman

ALLUMIN8 is revolutionizing healthcare with its groundbreaking 3D Therapeutic Hardware, a new category in Orthopedics & Spine aimed at reducing global reoperation rates and transforming surgical care. By integrating advanced porous designs with therapeutic functionality, ALLUMIN8 empowers surgeons to diagnose, treat, and heal through the device itself, marking a paradigm shift in medical technology. These innovations aim to deliver unmatched patient outcomes, are backed by the highest levels of clinical evidence and cutting-edge science, ensuring that each device not only performs mechanically but actively contributes to healing and recovery.

With a mission to redefine standards in surgical success, ALLUMIN8 pioneers solutions that address the root causes of complications, reduce revision surgeries, and improve healthcare efficiency worldwide. Our devices represent the pinnacle of engineering and clinical excellence, providing healthcare providers with tools to elevate care, improve recovery, and optimize costs. ALLUMIN8 is more than a MedTech company—it’s a catalyst for change, setting a new benchmark for therapeutic innovation in Orthopedics & Spine.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

The post 3DHEALS2025 Pitch3D Demo Day appeared first on 3DHeals.

Since 2018, 3DHEALS has decentralized its community activities from San Francisco, California, USA, to more than twenty cities throughout the world. This growth was mostly organic by motivated and special individuals, 3DHEALS Community Managers, who came from all walks of life ranging from techies, and designers, to entrepreneurs, doctors, and investors. The goal of these local groups and events aims to bridge the knowledge and experience gap between 3D printing, an emerging technology, and the established healthcare and life science innovation ecosystem. It takes a village to make things happen! On February 23rd, 2023, we will invite these local communities into our virtual arena on Zoom Event by hosting two one-hour virtual events (9-10 AM, and 4-5 PM Pacific Standard Time). We would like to invite our entire healthcare 3D printing and bioprinting ecosystem to meet our community managers from all over the world after a long hiatus due to the pandemic. We anticipate a revival of in-person events and likely hybrid events later this year. We will provide our audience with a new and unique experience through our new Zoom Event platform, with more ways to engage fellow attendees. We will get our community managers and local partner organizations to update us first and then attendees can freely visit the community “booths” and connect in small groups.

Speakers:

Vidya Chamundeswari Narasimhan

Dr. Vidya Chamundeswari Narasimhan is a Process Development Manager at STEMCELL Technologies, where she manages a team of Associates focused on the technology transfer of new products in the liquid cell culture Media Product Portfolio! She has previously worked as a division lead scientist at New Age Meats, developing food-grade matrices and culture media for cultivated cells. Vidya obtained her Doctorate by Research from Nanyang Technological University. Her Ph.D. work focused on developing bioactive polymeric scaffolds for tissue regeneration applications. She has interned at reputed universities and institutions such as MIT-Harvard (2013) and National Chemical Laboratory, Pune India (2012). She was the title winner of the Young Persons’ World Lecture Competition, in Australia (2017), and a finalist at the Falling Walls Lab Competition in Singapore (2019). At 3DHEALS, Vidya served as the Community Manager – San Francisco from 2019 – to 2022. She has contributed to expert corner blogs and organized networking events. She is currently based in Vancouver and is working towards setting up a 3DHEALS hub on the West Coast of Canada.

Ben Holmes

Dr. Benjamin Holmes is a seasoned entrepreneur, C-level executive, and inventor. He is the founder and CEO of Nanochon, a spin-out from his from lab at The George Washington University. He is also a founder, member of the board and executive at several other medical device and regenerative medicine companies. His PhD is in Mechanical Engineering, and focused on biomaterials and 3D printing for complex tissue regeneration and drug delivery.

Bill Harley

William is a Ph.D. candidate within the School of Biomedical Engineering at the University of Melbourne. He obtained a certificate 3 in business management and an honors degree in medical biotechnology from the University of New South Wales where he first entered research focusing on biomaterials, stem cells, and nanofabrication processes for tissue regeneration. Currently, his Ph.D. investigates the use of acoustic micromanipulation and 3D bioprinting as tools to pattern and define the cellular microenvironment. William has held roles as a research assistant and a business development consultant, where he currently serves as a community and events manager for 3D Heals and an organizing committee member for the Australian Bioprinting Workshop.

Dr. Ho Chaw Sing

Dr Ho Chaw Sing is the CEO of the National Additive Manufacturing Innovation Cluster (NAMIC), a Singapore government platform he co-founded as Managing Director at NTUitive in 2015 to catalyse innovation and scale industrial adoption of digital additive manufacturing technologies. Since its inception, NAMIC has orchestrated hundreds of public-private partnerships focusing on translational research to develop and deploy industry-relevant AM technologies and solutions across multiple industry sectors. Before joining the public sector, Chaw Sing was Head of Innovation and Strategic Partnerships at HP Singapore, Printing and Personal Systems Group. Prior to this, he was the Global Head for Consumer Inkjet Supplies Business operations, overseeing manufacturing supply chain operations and product innovation in HP. Chaw Sing began his career in the semiconductor industry with Chartered Semiconductor Manufacturing – now part of GlobalFoundries, in various customer-facing technology and engineering operation leadership roles.

Christle Koh

Christle Koh is the Head of Events and Marketing of the National Additive Manufacturing Innovation Cluster (NAMIC), a Singapore government platform formed to catalyse innovation and scale industrial adoption of digital additive manufacturing technologies. Since its inception in 2015, NAMIC has orchestrated hundreds of public-private partnerships focusing on translational research to develop and deploy industry-relevant AM technologies and solutions across multiple industry sectors. Prior to joining NAMIC, Christle has managed B2B events in various industries including advanced manufacturing, space technology, and transport logistics.

Joseph Borrello

Joe is currently the Lead Biomedical Engineer at Mount Sinai BioDesign, where he also recently received his PhD from the labs of Drs. Kevin Costa and Junqian Xu. In addition to his graduate work and helping lead engineering efforts within the Sinai BioDesign innovation team, Joe has been involved for many years in the leadership of GRO-Biotech, an inter-institutional, student-lead consortium focused on expanding career development opportunities for graduate students in and around the life sciences. More recently, he has also helped start the NYC chapter of Nucleate, a student-lead bio-entrepreneurship program focused on helping first-time scientific founders. Previously, Joe has worked at 3D Systems on technical development in the consumer marketing department and as a liaison with engineering project management teams, in addition to an earlier stint at experiential marketing firm Affinitive. Joe received his bachelors in Biomedical Engineering from Macaulay Honors College at The City College of New York, where he remains active in the Zahn Innovation Center, an on-campus tech startup incubator. He has also been involved in several startup ventures in the hardware and biotech spaces. Several years ago, Joe took Proto-Sauce, through NYCEDC’s Futureworks Incubator, with the goal of developing new materials for resin-based 3D printing. More recently, he had the privilege to serve as the CTO of BioSapien, using advanced manufacturing to create new devices for the treatment of cancer. Beyond his direct startup work, I’ve also continued to participate in Futureworks as a mentor, as well as others within the New York City startup community. Last, but not least, Joe is the writer and publisher of Magnitude and Direction (and it’s long-form companion Moment of Inertia), a bi-weekly email newsletter that focuses on some of my primary areas of interest, including bioengineering, data science, history, and cartography, as well as various events, opportunities, and goings-on in NYC revolving around the city’s growing technology and startup communities.

Ryan Harold

I live in the suburbs of Chicago, which is where I am originally from. I studied mechanical engineering as an undergraduate and then worked for several years as an engineer. I then transitioned into medicine and am an orthopedic surgeon. I focus on shoulder, elbow, and hand conditions. I have had a long interest in 3D modeling and 3D printing, especially as it pertains to orthopedics. 3D printing really combines my love of engineering with my passion for orthopedics.

Zsolt Pásztor

Zsolt is Co-founder and Managing Director of PREMET, a Hungarian MedTech company focusing on the production of medical devices, including patient specific implants, by additive manufacturing. The company puts a high emphasis on the continuous development of all elements of the production workflow – titanium 3D printing, thermal and surface treatment – and has been involved in several international R&D projects. Zsolt plays an important role in the management of the developments, and focuses especially on the improvement of the printing procedure and the different type of surface treatments. He is a Community Manager at 3DHEALS, co-founder and Vice-President of the Hungarian Additive Technology Association, Director of International Affairs and Leader of the “3D Printing in the Health Sector” working group of MediKlaszter, an accredited MedTech cluster. He was the Lead Expert of a recent Transnational Cooperation Project, aiming at collecting and disseminating best practices in the field of 3D Printing in the Health Sector in Central Europe.

Firoza Kothari

Firoza Kothari, Co-Founder & CTO – Anatomiz3D Medtech Pvt. Ltd. – A B.Tech in Biotechnology Engineering and now Forbes 30 under 30 – Asia – Healthcare and Science, 2020, Firoza Kothari started her journey to provide patient-specific medical solutions and one day end the organ donation problem by creating live organs out of patients’ stem cells. With that aspiration, she gave birth to Anatomiz3D, a startup focusing on medical 3D printing. She, along with her team, was the first to execute soft tissue models in India through Paediatric Cardiology, partial amputee prosthetic hand, the first kidney tumor case in India, and the model for tongue cancer was the first in the world. Being a Co-founder and CTO of Anatomiz3D, she, along with her team, has successfully added 3000 plus case studies. Her multi-disciplinary expertise prevails in converting 2D DICOM CT/MRI/Echo Scans to 3D Printed anatomical replicas, medical devices, and allied products, using various combinations of Hardware and Software, across multiple medical specializations. Anatomiz3D has played a vital role in creating the market for 3D Printing in the Medical industry in India since 2015 and is a pioneer for the same, also being the first in India to enable Hospital-Industry partnerships for Point-of-Care Labs.

Rafael Ramos

Reference contact for 3DHEAL for 3DHEALS Detroit/SE Michigan. Currently PhD candidate in Tissue Engineering exploring applications for FDM/SLA Bioprinting modalities to create drug testing template environments. I have some knowledge of the faculty at Wayne State University but I’m very interested in ensuring I have a solid sense of the field in Michigan (all universities and startup culture) and this part of the Midwest if anyone is interested in formalizing this line of communication. I grew up in Mexico City so I have also previously served as a communication link with the burgeoning bioprinting/3d printing culture in Mexico, specifically with some contacts out of the Tecnologico de Monterrey system. Happy to serve as a link to organizations like Latinx in BME and the Latino Medical Student Association. I also do some freelance work in spanish-language STEM communication should that need be usable in some capacity to anyone.

Hannah Riedle

Hannah has a background in mechanical engineering and focused her PhD on 3D printed soft anatomical models. Based on the results of her research she founded ANAMOS, a company developing configurable anatomical models Form surgical simulation.

Jim Long

Innovative therapy Consultant with a proven history of success in the healthcare industry. Passionate about developing and delivering the best solutions for patients. Strong sales professional skilled in: Structural Heart-TAVR, Vascular/Peripheral/Neurointerventional spaces. Actively working to build and strengthen the network of 3D printing in Healthcare!

Dr. Jenny Chen

Dr. Jenny Chen is trained as a San Francisco-based neuroradiologist, and the founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

The post 3DHEALS World Community Managers Festival appeared first on 3DHeals.

Based on popular demand, we are inviting industry and academic influencers to speak at our first “theme-based” webinar focusing on how artificial intelligence/machine learning is accelerating the 3D printing process and adoption.

The post Artificial Intelligence in Healthcare 3D Printing appeared first on 3DHeals.

Ohio is perhaps one of the most overlooked healthcare innovation hubs. In this webinar focusing on 3DHEALS Ohio community, we are featuring experts from academia and local businesses who are working on cool things that (you may not realize) are happening in Ohio.

The post 3DHEALS Ohio: Hidden Gems appeared first on 3DHeals.

3DHeals Melbourne is returning in 2021 to highlight local collaborative innovations in health care 3D technologies and to provide a virtual platform to foster crosstalk between clinicians, academia, and industry. The focus for this event will be on the real-world applications of biomedical engineering as we will hear from leading experts in the fields of 3D printing, 3D modeling/digital design, medical devices, and implants, followed by a discussion panel to breakdown similar challenges that lie ahead and how best to synergize research and development efforts moving forward.

3DHeals Melbourne welcomes all who are interested to learn more of the latest developments, practical applications, and future explorations of these exciting 3D medical technologies and how they can help shape the future of patient care.

The post 3DHeals Melbourne – 3D MedTech Innovation appeared first on 3DHeals.

3DHEALS2020 (June 5th-6th, 2020 )was the largest virtual summit this year, in the space of healthcare 3D printing/bioprinting, or elsewhere. This incredible virtual two-day summit gathered more than 70 world experts, 22 sessions. It is one of the most well-curated events that engage the audience to learn, think, and re-invent future healthcare.

We believe the recordings of this summit not long serve as a record of technological advances in time and space, but also a good starting point for anyone who is interested in working and investing in this unique space.

The post 3DHEALS2020 Summit Recordings appeared first on 3DHeals.